Department of Pediatrics, Cohen Children's Medical Center, Northwell Health, Queens, New York;
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York; and.
Pediatrics. 2020 Oct;146(4). doi: 10.1542/peds.2020-003186. Epub 2020 Jul 17.
We aim to describe the demographics, clinical presentation, hospital course, and severity of pediatric inpatients with coronavirus disease 2019 (COVID-19), with an emphasis on healthy, immunocompromised, and chronically ill children.
We conducted a single-center retrospective cohort study of hospitalized children aged younger than 22 years with COVID-19 infection at Steven and Alexandra Cohen Children's Medical Center at Northwell Health. Cases were identified from patients with fever and/or respiratory symptoms who underwent a nucleic acid amplification-based test for severe acute respiratory syndrome coronavirus 2.
Sixty-five patients were identified. The median age was 10.3 years (interquartile range, 1.4 months to 16.3 years), with 48% of patients older than 12 years and 29% of patients younger than 60 days of age. Fever was present in 86% of patients, lower respiratory symptoms or signs in 60%, and gastrointestinal symptoms in 62%. Thirty-five percent of patients required ICU care. The white blood cell count was elevated in severe disease ( = .0027), as was the C-reactive protein level ( = .0192), compared with mild and moderate disease. Respiratory support was required in 34% of patients. Severity was lowest in infants younger than 60 days of age and highest in chronically ill children; 79% of immunocompromised children had mild disease. One death was reported.
Among children who are hospitalized for COVID-19, most are younger than 60 days or older than 12 years of age. Children may have severe infection requiring intensive care support. The clinical course of immunocompromised patients was not more severe than that of other children. Elevated white blood cell count and C-reactive protein level are associated with greater illness severity.
我们旨在描述患有 2019 年冠状病毒病(COVID-19)的儿科住院患者的人口统计学、临床表现、住院过程和严重程度,重点关注健康、免疫功能低下和患有慢性病的儿童。
我们对在诺斯韦尔健康史蒂文和亚历山德拉·科恩儿童医疗中心住院的年龄小于 22 岁的 COVID-19 感染患儿进行了一项单中心回顾性队列研究。通过对患有发热和/或呼吸道症状的患者进行基于核酸扩增的严重急性呼吸系统综合征冠状病毒 2 检测,确定了病例。
共确定了 65 例患者。中位年龄为 10.3 岁(四分位距,1.4 个月至 16.3 岁),48%的患者年龄大于 12 岁,29%的患者年龄小于 60 天。86%的患者有发热,60%的患者有下呼吸道症状或体征,62%的患者有胃肠道症状。35%的患者需要重症监护治疗。与轻症和中度疾病相比,重症疾病的白细胞计数升高(=.0027),C 反应蛋白水平升高(=.0192)。34%的患者需要呼吸支持。60 天以下的婴儿疾病严重程度最低,慢性病儿童最高;79%的免疫功能低下儿童为轻症。报告了 1 例死亡。
在因 COVID-19 住院的儿童中,大多数年龄小于 60 天或大于 12 岁。儿童可能患有严重感染,需要重症监护支持。免疫功能低下患者的临床病程并不比其他儿童更严重。白细胞计数和 C 反应蛋白水平升高与疾病严重程度增加相关。